23/04/2025 – AB Science announces today that the European Medicines Agency (EMA) Committee for Orphan Medicinal Products (COMP) granted orphan drug status to AB8939 for the treatment of acute myeloid leukemia (AML) Download PDF Post navigationPreviousPrevious post:AB Science receives notice of allowance for Unites States patent covering masitinib until 2040 in the treatment of sickle cell diseaseNextNext post:AB Science will publish its 2024 annual financial report on May 9, 2025Related PostsAB Science announces EMA approval of Masivet shelf-life extension to 4 yearsJune 9, 2025AB Science announces the settlement delivery of its latest capital increase for €1.8 millionMay 23, 2025AB Science announces the successful completion of a EUR 1.8 million private placementMay 20, 2025AB Science receives Chinese patent protecting masitinib in the treatment of Covid-19 until 2041May 19, 2025AB Science reports a new publication in the scientific journal PLOS OneMay 15, 2025CNews – Interview of Alain MoussyMay 12, 2025
AB Science announces the settlement delivery of its latest capital increase for €1.8 millionMay 23, 2025
AB Science receives Chinese patent protecting masitinib in the treatment of Covid-19 until 2041May 19, 2025
